Ethos Technologies
LIFEaTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate …
© Wikipedia /
Creative Commons CC-BY-SA 3.0
more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Ethos Technologies
Subscribe RSS| Date | Type | Ø-Price | Volume |
|---|---|---|---|
| 7/28/2026 | Sell | $18.9 | $2,232,761 |
| 7/27/2026 | Sell | $19.5 | $3,832,848 |
| 7/24/2026 | Sell | $18.9 | $442,001 |
| 7/23/2026 | Sell | $19.1 | $1,206,270 |
| 7/22/2026 | Sell | $19.2 | $953,467 |
| 7/21/2026 | Sell | $19.4 | $436,368 |
| 7/20/2026 | Sell | $18.9 | $346,859 |
| 7/17/2026 | Sell | $18.7 | $383,614 |
| 7/16/2026 | Sell | $18.7 | $367,008 |
| 7/15/2026 | Sell | $19.3 | $1,464,685 |
| 5/15/2026 | Sell | $23.8 | $2,077,479 |
| 5/15/2026 | Sell | $22.3 | $128,435 |
| 5/15/2026 | Sell | $22.3 | $1,783,697 |
| 5/15/2026 | Sell | $22.4 | $1,024,561 |
| 5/15/2026 | Sell | $22.4 | $1,324,783 |
| 5/14/2026 | Sell | $23.0 | $1,382,330 |
| 1/30/2026 | Sell | $19.0 | $35,060,852 |
| 1/30/2026 | Buy | $19.0 | $4,949,975 |
| 1/30/2026 | Sell | $17.9 | $2,905,411 |
| 1/30/2026 | Sell | $17.9 | $221,964 |
| 1/30/2026 | Sell | $17.9 | $3,572,000 |
| 1/30/2026 | Buy | $19.0 | $99,997 |
| 1/29/2026 | Buy | $19.0 | $4,949,975 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)